

- Carbone M, Kratzke RA, Testa JR. The pathogenesis of mesothelioma. *Semin Oncol* 2002;29:2–17.
- Yang H, Bocchetta M, Kroczyńska B, et al. TNF-alpha inhibits asbestos-induced cytotoxicity via a NF-kappaB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis. *Proc Natl Acad Sci U S A* 2006;103:10397–10402.
- Altomare DA, Vaslet CA, Skele KL, et al. A mouse model recapitulating molecular features of human mesothelioma. *Cancer Res* 2005;65:8090–8095.
- Wagner JC, Berry G, Timbrell V. Mesotheliomata in rats after inoculation with asbestos and other materials. *Br J Cancer* 1973;28:173–185.
- Smith WE. Asbestos, talc and nitrites in relation to gastric cancer. *Am Ind Hyg Assoc J* 1973;34:227–228.
- Stanton MF, Wrench C. Mechanisms of mesothelioma induction with asbestos and fibrous glass. *J Natl Cancer Inst* 1972;48:797–821.
- Mossman BT, Bignon J, Corn M, et al. Asbestos: scientific developments and implications for public policy. *Science* 1990;247:294–301.
- Smith AH, Wright CC. Chrysotile asbestos is the main cause of pleural mesothelioma. *Am J Ind Med* 1996;30:252–266.
- Vianna NJ, Polan AK. Non-occupational exposure to asbestos and malignant mesothelioma in females. *Lancet* 1978;1:1061–1063.
- Li FP, Lokich J, Lapey J, et al. Familial mesothelioma after intense asbestos exposure at home. *JAMA* 1978;240:467.
- Yates DH, Corrin B, Stüldolph PN, et al. Malignant mesothelioma in south east England: clinicopathological experience of 272 cases. *Thorax* 1997;52:507–512.
- Yang H, Rivera Z, Jube S, et al. Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation. *Proc Natl Acad Sci U S A* 2010;107:12611–12616.
- Carbone M, Ly BH, Dodson RF, et al. Malignant mesothelioma: facts, myths, and hypotheses. *J Cell Physiol* 2012;227:44–58.
- Hillegeas JM, Shukla A, Lathrop SA, et al. Inflammation precedes the development of human malignant mesotheliomas in a SCID mouse xenograft model. *Ann N Y Acad Sci* 2010;1203:7–14.
- Wang Y, Faux SP, Hallden G, et al. Interleukin-1beta and tumour necrosis factor-alpha promote the transformation of human immortalised mesothelial cells by erionite. *Int J Oncol* 2004;25:173–178.
- Franchi L, Eigenbrod T, Munoz-Planillo R, et al. The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis. *Nat Immunol* 2009;10:241–247.
- Martinon F, Mayor A, Tschopp J. The inflammasomes: guardians of the body. *Annu Rev Immunol* 2009;27:229–265.
- Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. *J Leukoc Biol* 2007;81:1–5.
- Dostert C, Pettrilli V, Van Bruggen R, et al. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. *Science* 2008;320:674–677.
- Cassel SL, Eisenbarth SC, Iyer SS, et al. The Nalp3 inflammasome is essential for the development of silicosis. *Proc Natl Acad Sci U S A* 2008;105:9035–9040.
- Ellerman JE, Brown CK, de Vera M, et al. Masquerader: high mobility group box-1 and cancer. *Clin Cancer Res* 2007;13:2836–2848.
- Jube S, Rivera ZS, Bianchi ME, et al. Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma. *Cancer Res* 2012;72:3290–3301.
- Lamphear BP, Buncher CR. Latent period for malignant mesothelioma of occupational origin. *J Occup Med* 1992;34:718–721.
- De Rienzo A, Testa JR. Recent advances in the molecular analysis of human malignant mesothelioma. *Clin Ter* 2000;151:433–438.
- Ivanov SV, Miller J, Lucito R, et al. Genomic events associated with progression of pleural malignant mesothelioma. *Int J Cancer* 2009;124:589–599.
- Cheng JQ, Jhanwar SC, Klein WM, et al. p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. *Cancer Res* 1994;54:5547–5551.
- Kobayashi N, Toyooka S, Yanai H, et al. Frequent p16 inactivation by homozygous deletion or methylation is associated with a poor prognosis in Japanese patients with pleural mesothelioma. *Lung Cancer* 2008;62:120–125.
- Altomare DA, Menges CW, Xu J, et al. Losses of both products of the Cdkn2a/Arf locus contribute to asbestos-induced mesothelioma development and cooperate to accelerate tumorigenesis. *PLoS One* 2011;6:e18828.
- Yang CT, You L, Uematsu K, et al. p14(ARF) modulates the cytolytic effect of ONYX-015 in mesothelioma cells with wild-type p53. *Cancer Res* 2001;61:5959–5963.
- Yang CT, You L, Lin YC, et al. A comparison analysis of anti-tumor efficacy of adenoviral gene replacement therapy (p14ARF and p16INK4A) in human mesothelioma cells. *Anticancer Res* 2003;23:33–38.
- Dacic S, Kothmaier H, Land S, et al. Prognostic significance of p16/cdkn2a loss in pleural malignant mesotheliomas. *Virchows Arch* 2008;453:627–635.
- Ivanov SV, Goparaju CM, Lopez P, et al. Pro-tumorigenic effects of miR-31 loss in mesothelioma. *J Biol Chem* 2010;285:22809–22817.
- Marsella JM, Liu BL, Vaslet CA, et al. Susceptibility of p53-deficient mice to induction of mesothelioma by crocidolite asbestos fibers. *Environ Health Perspect* 1997;105:1069–1072.
- Amin KM, Litzky LA, Smythe WR, et al. Wilms' tumor 1 susceptibility (WT1) gene products are selectively expressed in malignant mesothelioma. *Am J Pathol* 1995;146:344–356.
- Zauderer MC, Krug LM. Novel therapies in phase II and III trials for malignant pleural mesothelioma. *J Natl Compr Canc Netw* 2012;10:42–47.
- Cheng JQ, Lee WC, Klein MA, et al. Frequent mutations of NF2 and allelic loss from chromosome band 22q12 in malignant mesothelioma: evidence for a two-hit mechanism of NF2 inactivation. *Genes Chromosomes Cancer* 1999;24:238–242.
- Thurneysen C, Opitz I, Kurtz S, et al. Functional inactivation of NF2/merlin in human mesothelioma. *Lung Cancer* 2009;64:140–147.
- Jongsma J, van Montfort E, Vooijs M, et al. A conditional mouse model for malignant mesothelioma. *Cancer Cell* 2008;13:261–271.
- Gerwin BI, Lechner JF, Reddel RR, et al. Comparison of production of transforming growth factor-beta and platelet-derived growth factor by normal human mesothelial cells and mesothelioma cell lines. *Cancer Res* 1987;47:6180–6184.
- Honda M, Kanno T, Fujita Y, et al. Mesothelioma cell proliferation through autocrine activation of PDGF-beta receptor. *Cell Physiol Biochem* 2012;29:667–674.
- Jahan T, Gu L, Kratzke R, et al. Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107). *Lung Cancer* 2012;76:393–396.
- Kumar-Singh S, Weyler J, Martin MJ, et al. Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and -2, and TGF-beta expression. *J Pathol* 1999;189:72–78.
- Maeda J, Ueki N, Ohkawa T, et al. Transforming growth factor-beta 1 (TGF-beta 1)- and beta 2-like activities in malignant pleural effusions caused by malignant mesothelioma or primary lung cancer. *Clin Exp Immunol* 1994;98:319–322.
- Kim S, Buchlis G, Fridlender ZG, et al. Systemic blockade of transforming growth factor-beta signaling augments the efficacy of immunogene therapy. *Cancer Res* 2008;68:10247–10256.
- Kissick HT, Ireland DJ, Krishnan S, et al. Tumour eradication and induction of memory against murine mesothelioma by combined immunotherapy. *Immunol Cell Biol* 2012;90:822–826.
- Lee TC, Zhang Y, Aston C, et al. Normal human mesothelial cells and mesothelioma cell lines express insulin-like growth factor I and associated molecules. *Cancer Res* 1995;55:2858–2864.
- Pass HI, Mew DJ, Carbone M, et al. The effect of an antisense expression plasmid to the IGF-1 receptor on hamster mesothelioma proliferation. *Dev Biol Stand* 1998;94:321–328.
- Kalra N, Zhang J, Yu Y, et al. Efficacy of anti-insulin-like growth factor I receptor monoclonal antibody cixutumumab in mesothelioma is highly correlated with insulin growth factor-I receptor sites/cell. *Int J Cancer* 2012;131:2143–2152.
- Nakano T, Chahinian AP, Shinjo M, et al. Interleukin 6 and its relationship to clinical parameters in patients with malignant pleural mesothelioma. *Br J Cancer* 1998;77:907–912.
- Adachi Y, Aoki C, Yoshio-Hoshino N, et al. Interleukin-6 induces both cell growth and VEGF production in malignant mesotheliomas. *Int J Cancer* 2006;119:1303–1311.
- Antony VB, Hott JW, Godbey SW, et al. Angiogenesis in mesotheliomas. Role of mesothelial cell derived IL-8. *Chest* 1996;109:21S–22S.
- Ohta Y, Shridhar V, Bright RK, et al. VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. *Br J Cancer* 1999;81:54–61.
- Kumar-Singh S, Vermeulen PB, Weyler J, et al. Evaluation of tumour angiogenesis as a prognostic marker in malignant mesothelioma. *J Pathol* 1997;182:211–216.
- Ohta Y, Shridhar V, Kalemkerian GP, et al. Thrombospondin-1 expression and clinical implications in malignant pleural mesothelioma. *Cancer* 1999;85:2570–2576.
- Gazdar AF, Butel JS, Carbone M. SV40 and human tumours: myth, association or causality? *Nat Rev Cancer* 2002;2:957–964.
- Carbone M, Pass HI. Evolving aspects of mesothelioma carcinogenesis: SV40 and genetic predisposition. *J Thorac Oncol* 2006;1:169–171.
- Carbone M, Strianese O, Theos K, et al. Mesothelioma. *Hawaii Med J* 2007;66:48–50.
- Klein G. Simian virus 40 and the human mesothelium. *Proc Natl Acad Sci U S A* 2000;97:9830–9831.
- Cicala C, Pompetti F, Carbone M. SV40 induces mesotheliomas in hamsters. *Am J Pathol* 1993;142:1524–1533.
- Kroczyńska B, Cutrone R, Bocchetta M, et al. Crocidolite asbestos and SV40 are cocarcinogens in human mesothelial cells and in causing mesothelioma in hamsters. *Proc Natl Acad Sci U S A* 2006;103:14128–14133.
- Cleaver AL, Bhamidipaty K, Wylie B, et al. Long-term exposure of mesothelial cells to SV40 and asbestos leads to malignant transformation and chemotherapy resistance. *Carcinogenesis* 2014;35:407–414.
- Dresselhaus MS, Dresselhaus G, Charlier JC, et al. Electronic, thermal and mechanical properties of carbon nanotubes. *Philos Trans A Math Phys Eng Sci* 2004;362:2065–2098.

63. Lam CW, James JT, McCluskey R, et al. Pulmonary toxicity of single-wall carbon nanotubes in mice 7 and 90 days after intratracheal instillation. *Toxicol Sci* 2004;77:126–134.
64. Shvedova AA, Kagan VE, Fadeel B. Close encounters of the small kind: adverse effects of man-made materials interfacing with the nano-cosmos of biological systems. *Annu Rev Pharmacol Toxicol* 2010;50:63–88.
65. Shvedova AA, Kisin E, Murray AR, et al. Inhalation vs. aspiration of single-walled carbon nanotubes in C57BL/6 mice: inflammation, fibrosis, oxidative stress, and mutagenesis. *Am J Physiol Lung Cell Mol Physiol* 2008;295:L552–L565.
66. Takagi A, Hirose A, Futakuchi M, et al. Dose-dependent mesothelioma induction by intraperitoneal administration of multi-wall carbon nanotubes in p53 heterozygous mice. *Cancer Sci* 2012;103:1440–1444.
67. Takagi A, Hirose A, Nishimura T, et al. Induction of mesothelioma in p53+/- mouse by intraperitoneal application of multi-wall carbon nanotube. *J Toxicol Sci* 2008;33:105–116.
68. Pacurari M, Castranova V, Vallyathan V. Single- and multi-wall carbon nanotubes versus asbestos: are the carbon nanotubes a new health risk to humans? *J Toxicol Environ Health A* 2010;73:378–395.
69. Pacurari M, Yin XJ, Zhao J, et al. Raw single-wall carbon nanotubes induce oxidative stress and activate MAPKs, AP-1, NF-kappaB, and Akt in normal and malignant human mesothelial cells. *Environ Health Perspect* 2008;116:1211–1217.
70. Clista-Baker EE, Taylor AJ, Sayers BC, et al. Nickel nanoparticles enhance platelet-derived growth factor-induced chemokine expression by mesothelial cells via prolonged mitogen-activated protein kinase activation. *Am J Respir Cell Mol Biol* 2012;47:552–561.
71. Carbone M, Emri S, Dogan AU, et al. A mesothelioma epidemic in Cappadocia: scientific developments and unexpected social outcomes. *Nat Rev Cancer* 2007;7:147–154.
72. Carbone M, Baris YI, Bertino P, et al. Erionite exposure in North Dakota and Turkish villages with mesothelioma. *Proc Natl Acad Sci U S A* 2011;108:13618–13623.
73. Dogan AU, Dogan M, Hoskins JA. Erionite series minerals: mineralogical and carcinogenic properties. *Environ Geochem Health* 2008;30(4):367–381.
74. Ascoli V, Aalto Y, Carnovale-Scalzo C, et al. DNA copy number changes in familial malignant mesothelioma. *Cancer Genet Cytogenet* 2001;127:80–82.
75. Carbone M, Yang H, Pass HI, et al. BAP1 and cancer. *Nat Rev Cancer* 2013;13:153–159.
76. Dey A, Seshasayee D, Noubade R, et al. Loss of the tumor suppressor BAP1 causes myeloid transformation. *Science* 2012;337:1541–1546.
77. Bott M, Brevet M, Taylor BS, et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. *Nat Genet* 2011;43:668–672.
78. Matatall KA, Agapova OA, Onken MD, et al. BAP1 deficiency causes loss of melanocytic cell identity in uveal melanoma. *BMC Cancer* 2013;13:371.
79. Zauderer MG, Bott M, McMillan R, et al. Clinical characteristics of patients with malignant pleural mesothelioma harboring somatic BAP1 mutations. *J Thorac Oncol* 2013;8:1430–1433.
80. Yoshikawa Y, Sato A, Tsujimura T, et al. Frequent inactivation of the BAP1 gene in epithelioid-type malignant mesothelioma. *Cancer Sci* 2012;103:868–874.
81. Arzt L, Quehenberger F, Halbwed I, et al. BAP1 protein is a progression factor in malignant pleural mesothelioma. *Pathol Oncol Res* 2014;20:145–151.
82. Testa JR, Cheung M, Pei J, et al. Germline BAP1 mutations predispose to malignant mesothelioma. *Nat Genet* 2011;43:1022–1025.
83. Robinson LA. Solitary fibrous tumor of the pleura. *Cancer Control* 2006;13:264–269.
84. Brozzetti S, D'Andrea N, Limiti MR, et al. Clinical behavior of solitary fibrous tumors of the pleura. An immunohistochemical study. *Anticancer Res* 2000;20:4701–4706.
85. Filosso PL, Oliaro A, Rena O, et al. Severe hypoglycaemia associated with a giant solitary fibrous tumor of the pleura. *J Cardiovasc Surg (Torino)* 2002;43:559–561.
86. Carbone M, Rizzo P, Powers A, et al. Molecular analyses, morphology and immunohistochemistry together differentiate pleural synovial sarcomas from mesotheliomas: clinical implications. *Anticancer Res* 2002;22:3443–3448.
87. Gee GV, Koestler DC, Christensen BC, et al. Downregulated microRNAs in the differential diagnosis of malignant pleural mesothelioma. *Int J Cancer* 2010;127:2859–2869.
88. Benjamin H, Lebanony D, Rosenwald S, et al. A diagnostic assay based on microRNA expression accurately identifies malignant pleural mesothelioma. *J Mol Diagn* 2010;12:771–779.
89. Lin RT, Takahashi K, Karjalainen A, et al. Ecological association between asbestos-related diseases and historical asbestos consumption: an international analysis. *Lancet* 2007;369:844–849.
90. Peto J, Decarli A, La Vecchia C, et al. The European mesothelioma epidemic. *Br J Cancer* 1999;79:666–672.
91. Roggli VL, Sharma A, Butnor KJ, et al. Malignant mesothelioma and occupational exposure to asbestos: a clinicopathological correlation of 1445 cases. *Ultrastruct Pathol* 2002;26:55–65.
92. Wolf AS, Richards WC, Tillemann TR, et al. Characteristics of malignant pleural mesothelioma in women. *Ann Thorac Surg* 2010;90:949–956.
93. Erasmus JJ, Truong MT, Smythe WR, et al. Integrated computed tomography-positron emission tomography in patients with potentially resectable malignant pleural mesothelioma: Staging implications. *J Thorac Cardiovasc Surg* 2005;129:1364–1370.
94. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. *J Clin Oncol* 2003;21:2636–2644.
95. Herndon JE, Green MR, Chahinian AP, et al. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. *Chest* 1998;113:723–731.
96. Robinson BW, Creaney J, Lake R, et al. Mesothelin-family proteins and diagnosis of mesothelioma. *Lancet* 2003;362:1612–1616.
97. Beyer HL, Geschwindt RD, Glover CL, et al. MESOMARK: a potential test for malignant pleural mesothelioma. *Clin Chem* 2007;53:666–672.
98. Pass HI, Wali A, Tang N, et al. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions. *Ann Thorac Surg* 2008;85:265–272.
99. Hollevoet K, Reitsma JB, Creaney J, et al. Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. *J Clin Oncol* 2012;30:1541–1549.
100. Creaney J, Robinson BW. Detection of malignant mesothelioma in asbestos-exposed individuals: the potential role of soluble mesothelin-related protein. *Hematol Oncol Clin North Am* 2005;19:1025–1040, v.
101. Park EK, Sandrini A, Yates DH, et al. Soluble mesothelin-related protein in an asbestos-exposed population: the dust diseases board cohort study. *Am J Respir Crit Care Med* 2008;178:832–837.
102. Imashimizu K, Shiomi K, Maeda M, et al. Feasibility of large-scale screening using N-ERC/mesothelin levels in the blood for the early diagnosis of malignant mesothelioma. *Exp Ther Med* 2011;2:409–411.
103. Sandhu H, Dehnen W, Roller M, et al. mRNA expression patterns in different stages of asbestos-induced carcinogenesis in rats. *Carcinogenesis* 2000;21:1023–1029.
104. Pass HI, Lott D, Lonardo F, et al. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. *N Engl J Med* 2005;353:1564–1573.
105. Grigoriu BD, Grigoriu C, Chahine B, et al. Clinical utility of diagnostic markers for malignant pleural mesothelioma. *Monaldi Arch Chest Dis* 2009;71:31–38.
106. Creaney J, Yeoman D, Demelker Y, et al. Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma. *J Thorac Oncol* 2008;3:851–857.
107. Pass HI, Levin SM, Harbut MR, et al. Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. *N Engl J Med* 2012;367:1417–1427.
108. Wechsler RJ, Rao VM, Steiner RM. The radiology of thoracic malignant mesothelioma. *Crit Rev Diagn Imaging* 1984;20:283–310.
109. Heller RM, Janower ML, Weber AL. The radiological manifestations of malignant pleural mesothelioma. *Am J Roentgenol Radium Ther Nucl Med* 1970;108:53–59.
110. Solomon A. Radiological features of diffuse mesothelioma. *Environ Res* 1970;3:330–338.
111. Patz EF Jr, Shaffer K, Piwnica-Worms DR, et al. Malignant pleural mesothelioma: value of CT and MR imaging in predicting resectability. *AJR Am J Roentgenol* 1992;159:961–966.
112. Flores RM. The role of PET in the surgical management of malignant pleural mesothelioma. *Lung Cancer* 2005;49:S27–S32.
113. Schneider DB, Clary-Macy C, Challa S, et al. Positron emission tomography with fl-18-fluorodeoxyglucose in the staging and preoperative evaluation of malignant pleural mesothelioma. *J Thorac Cardiovasc Surg* 2000;120:128–133.
114. Benard F, Sterman D, Smith RJ, et al. Prognostic value of FDG PET imaging in malignant pleural mesothelioma. *J Nucl Med* 1999;40:1241–1245.
115. Gerbaudo VH, Mamede M, Trotman-Dickenson B, et al. FDG PET/CT patterns of treatment failure of malignant pleural mesothelioma: relationship to histologic type, treatment algorithm, and survival. *Eur J Nucl Med Mol Imaging* 2011;38:810–821.
116. Gerbaudo VH, Sugarbaker DJ, Britz-Cunningham S, et al. Assessment of malignant pleural mesothelioma with (18)F-FDG dual-head gamma-camera coincidence imaging: comparison with histopathology. *J Nucl Med* 2002;43:1144–1149.
117. Boutin C, Rey F, Gouvernet J, et al. Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Part 2: Prognosis and staging. *Cancer* 1993;72:394–404.
118. Boutin C, Rey F. Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Part 1: Diagnosis. *Cancer* 1993;72:389–393.
119. Boutin C, Rey F, Viallat JR. Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy. *Chest* 1995;108:754–758.
120. Muirhead R, O'Rourke N. Drain site radiotherapy in malignant pleural mesothelioma: a wasted resource. *Eur Respir J* 2007;30:1021–1025.
121. O'Rourke N, Garcia JC, Paul J, et al. A randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma. *Radiation Oncol* 2007;84:18–22.
122. Antman KH, Blum RH, Greenberger JS, et al. Multimodality therapy for malignant mesothelioma based on a study of natural history. *Am J Med* 1980;68:356–362.

123. Law MR, Hodson ME, Heard BE. Malignant mesothelioma of the pleura: relation between histological type and clinical behaviour. *Thorax* 1982;37:810–815.
124. Falconieri G, Grandi G, DiBonito L, et al. Intracranial metastases from malignant pleural mesothelioma. Report of three autopsy cases and review of the literature. *Arch Pathol Lab Med* 1991;115:591–595.
125. Davies MJ, Ahmedzai S, Arsiwala SS, et al. Intracranial metastases from malignant pleural mesothelioma. *Scand J Thorac Cardiovasc Surg* 1995;29:97–99.
126. Curran D, Sahnoud T, Therasse P, et al. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. *J Clin Oncol* 1998;16:145–152.
127. Fennell DA, Parmar A, Shamash J, et al. Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials. *J Clin Oncol* 2005;23:184–189.
128. Edwards JG, Abrams KR, Levermore JN, et al. Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems. *Thorax* 2000;55:731–735.
129. Kao SC, Vardy J, Chatfield M, et al. Validation of prognostic factors in malignant pleural mesothelioma: a retrospective analysis of data from patients seeking compensation from the New South Wales Dust Diseases Board. *Clin Lung Cancer* 2013;14:70–77.
130. Kao SC, Klebe S, Henderson DW, et al. Low calretinin expression and high neutrophil-to-lymphocyte ratio are poor prognostic factors in patients with malignant mesothelioma undergoing extrapleural pneumonectomy. *J Thorac Oncol* 2011;6:1923–1929.
131. Kao SC, Pavlakis N, Harvie R, et al. High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. *Clin Cancer Res* 2010;16:5805–5813.
132. Meniawy TM, Creaney J, Lake RA, et al. Existing models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma. *Br J Cancer* 2013;109:1813–1820.
133. Gordon GJ, Jensen RV, Hsiao LL, et al. Using gene expression ratios to predict outcome among patients with mesothelioma. *J Natl Cancer Inst* 2003;95:598–605.
134. Pass HI, Liu Z, Wali A, et al. Gene expression profiles predict survival and progression of pleural mesothelioma. *Clin Cancer Res* 2004;10:849–859.
135. Lopez-Rios F, Chuai S, Flores R, et al. Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction. *Cancer Res* 2006;66:2970–2979.
136. Pass HI, Goparaju C, Ivanov S, et al. hsa-miR-29c* is linked to the prognosis of malignant pleural mesothelioma. *Cancer Res* 2010;70:1916–1924.
137. Righi L, Papotti MG, Ceppi P, et al. Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy. *J Clin Oncol* 2010;28:1534–1539.
138. Hollevoet K, Nackaerts K, Gosselin R, et al. Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma. *J Thorac Oncol* 2011;6:1930–1937.
139. Cappia S, Righi L, Mirabelli D, et al. Prognostic role of osteopontin expression in malignant pleural mesothelioma. *Am J Clin Pathol* 2008;130:58–64.
140. Ivanova AV, Goparaju CM, Ivanov SV, et al. Protumorigenic role of HAPLN1 and its IgV domain in malignant pleural mesothelioma. *Clin Cancer Res* 2009;15:2602–2611.
141. Gerbaudo VH, Britz-Cunningham S, Sugarbaker DJ, et al. Metabolic significance of the pattern, intensity and kinetics of 18F-FDG uptake in malignant pleural mesothelioma. *Thorax* 2003;58:1077–1082.
142. Sharif S, Zahid I, Routledge T, et al. Does positron emission tomography offer prognostic information in malignant pleural mesothelioma? *Interact Cardiovasc Thorac Surg* 2011;12:806–811.
143. Lee HY, Hyun SH, Lee KS, et al. Volume-based parameter of 18F-FDG PET/CT in malignant pleural mesothelioma: prediction of therapeutic response and prognostic implications. *Ann Surg Oncol* 2010;17:2787–2794.
144. Nowak AK, Francis RJ, Phillips MJ, et al. A novel prognostic model for malignant mesothelioma incorporating quantitative FDG-PET imaging with clinical parameters. *Clin Cancer Res* 2010;16:2409–2417.
145. Butchart EG, Ashcroft T, Bamsley WC, et al. Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients. *Thorax* 1976;31:15–24.
146. Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. *Chest* 1995;108:1122–1128.
147. Rusch VW, Giroux D, Kennedy C, et al. Initial analysis of the international association for the study of lung cancer mesothelioma database. *J Thorac Oncol* 2012;7:1631–1639.
148. Zellos L, Sugarbaker DJ. Current surgical management of malignant pleural mesothelioma. *Curr Oncol Rep* 2002;4:354–360.
149. Richards WG, Godleski JJ, Yeap BY, et al. Proposed adjustments to pathologic staging of epithelial malignant pleural mesothelioma based on analysis of 354 cases. *Cancer* 2010;116:1510–1517.
150. Pass HI, Temeck BK, Kranda K, et al. Preoperative tumor volume is associated with outcome in malignant pleural mesothelioma. *J Thorac Cardiovasc Surg* 1998;115:310–317.
151. Gill RR, Richards WG, Yeap BY, et al. Epithelial malignant pleural mesothelioma after extrapleural pneumonectomy: stratification of survival with CT-derived tumor volume. *AJR Am J Roentgenol* 2012;198:359–363.
152. Richards W, Gill RR, Yeap B, et al. Validation of a stage-independent pre-operative risk assessment algorithm for patients considering surgery for malignant pleural mesothelioma. Presented at the 15th International Association for the Study of Lung Cancer Meeting, October 2013, Sydney, Australia.
153. Stahel RA, Weder W, Felip E. Malignant pleural mesothelioma: ESMO clinical recommendations for diagnosis, treatment and follow-up. *Ann Oncol* 2009;20:73–75.
154. Pilling JE, Dusmet ME, Ladas G, et al. Prognostic factors for survival after surgical palliation of malignant pleural effusion. *J Thorac Oncol* 2010;5:1544–1550.
155. Rintoul RC, Ritchie AJ, Edwards JG, et al. MesoVATS: A multi-centre randomised controlled trial of video assisted thoracoscopic pleurectomy versus talc pleurodesis in malignant pleural mesothelioma (MesoVATS): an open-label, randomised, controlled trial. *Lancet* 2014;14:60418–60419.
156. Pien GW, Gant MJ, Washam CL, et al. Use of an implantable pleural catheter for trapped lung syndrome in patients with malignant pleural effusion. *Chest* 2001;119:1641–1646.
157. de Graaf-Strukowska L, van der Zee J, van Putten W, et al. Factors influencing the outcome of radiotherapy in malignant mesothelioma of the pleura—a single-institution experience with 189 patients. *Int J Radiat Oncol Biol Phys* 1999;43:511–516.
158. Bissett D, Macbeth FR, Cram I. The role of palliative radiotherapy in malignant mesothelioma. *Clin Oncol (R Coll Radiol)* 1991;3:315–317.
159. Butchart EG, Ashcroft T, Bamsley WC, et al. Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients. *Thorax* 1976;31:15–24.
160. Treasure T, Internullo E, Fiorentino F, et al. A survey of opinions and beliefs concerning surgery for malignant pleural mesothelioma amongst 802 members of the European Association for Cardio-Thoracic Surgery (EACTS), the European Society of Thoracic Surgeons (ESTS) and the Society of Thoracic Surgeons (STS). *Interact Cardiovasc Thorac Surg* 2011;12:341–346.
161. Kao SC, Yan TD, Lee K, et al. Accuracy of diagnostic biopsy for the histological subtype of malignant pleural mesothelioma. *J Thorac Oncol* 2011;6:602–605.
162. Bueno R, Reblando J, Glickman J, et al. Pleural biopsy: a reliable method for determining the diagnosis but not subtype in mesothelioma. *Ann Thorac Surg* 2004;78:1774–1776.
163. Rice D, Rusch V, Pass H, et al. Recommendations for uniform definitions of surgical techniques for malignant pleural mesothelioma: a consensus report of the international association for the study of lung cancer international staging committee and the international mesothelioma interest group. *J Thorac Oncol* 2011;6:1304–1312.
164. Cao CQ, Yan TD, Bannon PG, et al. A systematic review of extrapleural pneumonectomy for malignant pleural mesothelioma. *J Thorac Oncol* 2010;5:1692–1703.
165. Sugarbaker DJ, Wolf AS. Surgery for malignant pleural mesothelioma. *Expert Rev Respir Med* 2010;4:363–372.
166. Sugarbaker DJ, Jaklitsch MT, Bueno R, et al. Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies. *J Thorac Cardiovasc Surg* 2004;128:138–146.
167. Balduyck B, Trousse D, Nakas A, et al. Therapeutic surgery for nonepithelioid malignant pleural mesothelioma: is it really worthwhile? *Ann Thorac Surg* 2010;89:907–911.
168. Kindler HL, van Meerbeeck JP. The role of gemcitabine in the treatment of malignant mesothelioma. *Semin Oncol* 2002;29:70–76.
169. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. *J Clin Oncol* 2003;21:2636–2644.
170. Ahmad A, Stevens CW, Smyth WR, et al. Promising early local control of malignant pleural mesothelioma following postoperative intensity modulated radiotherapy (IMRT) to the chest. *Cancer J* 2003;9:476–484.
171. Pass HI, Temeck BK, Kranda K, et al. Phase III randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunotherapy for malignant pleural mesothelioma. *Ann Surg Oncol* 1997;4:628–633.
172. Treasure T, Lang-Lazdunski L, Waller D, et al. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. *Lancet Oncol* 2011;12:763–772.
173. Weder W, Stahel RA, Baas P, et al. The MARS feasibility trial: conclusions not supported by data. *Lancet Oncol* 2011;12:1093–1094.
174. Flores RM, Pass HI, Seshan VE, et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. *J Thorac Cardiovasc Surg* 2008;135:620–626.
175. Nakas A, Trousse DS, Martin-Ucar AE, et al. Open lung-sparing surgery for malignant pleural mesothelioma: the benefits of a radical approach within multimodality therapy. *Eur J Cardiothorac Surg* 2008;34:886–891.
176. Shahin Y, Wellham J, Jappie R, et al. How successful is lung-preserving radical surgery in the mesothelioma and radical surgery-trial environment? A case-controlled analysis. *Eur J Cardiothorac Surg* 2011;39:360–363.

177. Steele JP, Walley T, Edwards J. A randomized trial of extended pleurectomy and decortication with pemetrexed and platinum chemotherapy versus pemetrexed and platinum chemotherapy in patients with malignant pleural mesothelioma. Presented at International Mesothelioma Interest Group Meeting, October 2012, Boston, MA.
178. Lang-Lazdunski L, van Meerbeek JP. EORTC randomized phase II study of extended pleurectomy/decortication (E-Pd) preceded or followed by chemotherapy in patients with early stage malignant pleural mesothelioma (MPM). Presented at International Mesothelioma Interest Group Meeting, October 2012, Boston, MA.
179. Krug LM. An overview of chemotherapy for mesothelioma. *Hematol Oncol Clin North Am* 2005;19:1117-1136, vii.
180. Berghmans T, Paesmans M, Lalami Y, et al. Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis. *Lung Cancer* 2002;38:111-121.
181. Byrne MJ, Davidson JA, Musk AW, et al. Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. *J Clin Oncol* 1999;17:25-30.
182. Nowak AK, Byrne MJ, Williamson R, et al. A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. *Br J Cancer* 2002;87:491-496.
183. van Haarst JM, Baas P, Manegold C, et al. Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma. *Br J Cancer* 2002;86:342-345.
184. Favaretto AG, Aversa SM, Paccagnella A, et al. Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: a multicentric phase II study. *Cancer* 2003;97:2791-2797.
185. Andreopoulou E, Ross PJ, O'Brien ME, et al. The palliative benefits of MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in patients with malignant mesothelioma. *Ann Oncol* 2004;15:1406-1412.
186. Steele JP, Shamash J, Evans MT, et al. Phase II study of vinorelbine in patients with malignant pleural mesothelioma. *J Clin Oncol* 2000;18:3912-3917.
187. Muers MF, Stephens RJ, Fisher P, et al. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. *Lancet* 2008;371:1685-1694.
188. Chattopadhyay S, Moran RG, Goldman ID. Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications. *Mol Cancer Ther* 2007;6:404-417.
189. Bueno R, Appasani K, Mercer H, et al. The alpha folate receptor is highly activated in malignant pleural mesothelioma. *J Thorac Cardiovasc Surg* 2001;121:225-233.
190. Thodtmann R, Depenbrock H, Dumez H, et al. Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin. *J Clin Oncol* 1999;17:3009-3016.
191. Van Meerbeek JP, Caafar R, Manegold C, et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. *J Clin Oncol* 2005;23:6881-6889.
192. Ceresoli GL, Zucali PA, Favaretto AG, et al. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. *J Clin Oncol* 2006;24:1443-1448.
193. Castagneto B, Botta M, Aitini E, et al. Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM). *Ann Oncol* 2008;19:370-373.
194. Santoro A, O'Brien ME, Stahel RA, et al. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaive patients with malignant pleural mesothelioma: results of the International Expanded Access Program. *J Thorac Oncol* 2008;3:756-763.
195. Taylor P, Castagneto B, Dark C, et al. Single-agent pemetrexed for chemonaive and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program. *J Thorac Oncol* 2008;3:764-771.
196. Scagliotti GV, Shin DM, Kindler HL, et al. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. *J Clin Oncol* 2003;21:1556-1561.
197. Jassem J, Ramlau R, Santoro A, et al. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. *J Clin Oncol* 2008;26:1698-1704.
198. Janne PA, Wozniak AJ, Belani CP, et al. Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program. *J Thorac Oncol* 2006;1:506-512.
199. Zucali PA, Simonelli M, Michetti G, et al. Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey. *Lung Cancer* 2012;75:360-367.
200. Manegold C, Symanowski J, Gatzemeier U, et al. Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. *Ann Oncol* 2005;16:923-927.
201. Stebbing J, Powles T, McPherson K, et al. The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma. *Lung Cancer* 2009;63:94-97.
202. Masood R, Kundra A, Zhu S, et al. Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF-C autocrine loops. *Int J Cancer* 2003;104:603-610.
203. Strizzi L, Catalano A, Vianale G, et al. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. *J Pathol* 2001;193:468-475.
204. Konig J, Tolnay E, Wiethage T, et al. Co-expression of vascular endothelial growth factor and its receptor flt-1 in malignant pleural mesothelioma. *Respiration* 2000;67:36-40.
205. Linder C, Linder S, Munck-Wikland E, et al. Independent expression of serum vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in patients with carcinoma and sarcoma. *Anticancer Res* 1998;18:2063-2068.
206. Kindler HL, Karrison TG, Gandara DR, et al. Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. *J Clin Oncol* 2012;30:2509-2515.
207. Dowell JE, Dunphy FR, Taub RN, et al. A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma. *Lung Cancer* 2012;77:567-571.
208. Baas P, Boogerd W, Dalesio O, et al. Thalidomide in patients with malignant pleural mesothelioma. *Lung Cancer* 2005;48:291-296.
209. Buikhuizen WA, Burgers JA, Vincent AD, et al. Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study. *Lancet Oncol* 2013;14:543-551.
210. Langerak AW, De Laat PA, Van der Linden-Van Beurden CA, et al. Expression of platelet-derived growth factor (PDGF) and PDGF receptors in human malignant mesothelioma in vitro and in vivo. *J Pathol* 1996;178:151-160.
211. Catalano A, Rodilossi S, Rippon MR, et al. Induction of stem cell factor/c-kit/slug signal transduction in multidrug-resistant malignant mesothelioma cells. *J Biol Chem* 2004;279:46706-46714.
212. Kindler HL, Vogelzang NJ, Chien K, et al. SU5416 in malignant mesothelioma: A University of Chicago Phase II Consortium Study. *Proc Am Soc Clin Oncol* 2001;20:abstract 1359.
213. Dubey S, Janne PA, Krug L, et al. A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307. *J Thorac Oncol* 2010;5:1655-1661.
214. Nowak AK, Millward MJ, Creaney J, et al. A phase II study of intermittent sunitib malate as second-line therapy in progressive malignant pleural mesothelioma. *J Thorac Oncol* 2012;7:1449-1456.
215. Laurie SA, Gupta A, Chu Q, et al. Brief report: A phase II study of sunitib in malignant pleural mesothelioma. The NCIC Clinical Trials Group. *J Thorac Oncol* 2011;6:1950-1954.
216. Paik PK, Krug LM. Histone deacetylase inhibitors in malignant pleural mesothelioma: preclinical rationale and clinical trials. *J Thorac Oncol* 2010;5:275-279.
217. Marks PA, Richon VM, Miller T, et al. Histone deacetylase inhibitors. *Adv Cancer Res* 2004;91:137-168.
218. Krug LM, Curley T, Schwartz L, et al. Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid. *Clin Lung Cancer* 2006;7:257-261.
219. Krug L, Kindler H, Calvert AH. VANTAGE 014: Vorinostat in patients with advanced malignant pleural mesothelioma who have failed prior pemetrexed and etehr cisplatin or carboplatin therapy: a phase III, randomized, double-blind, placebo-controlled trial. *Eur J Cancer* 2011;1:2-3.
220. Okada T, Lopez-Lago M, Giancotti FG. Merlin/NF-2 mediates contact inhibition of growth by suppressing recruitment of Rac to the plasma membrane. *J Cell Biol* 2005;171:361-371.
221. Lopez-Lago MA, Okada T, Murillo MM, et al. Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling. *Mol Cell Biol* 2009;29:4235-4249.
222. Garland L, Ou G, Moon J, et al. SWOG 0722: A phase II study of mTOR inhibitor everolimus (RAD001) in malignant pleural mesothelioma (MPM). *J Clin Oncol* 2012;30(Suppl): Abst. 7083.
223. Kindler H, Dolly S, Bendell J, et al. Evaluation of tolerability and antitumor activity of GDC-0980, an oral PI3K/mTOR inhibitor, administered to patients with advanced malignant pleural mesothelioma. Paper presented at: 11th International Conference of the International Mesothelioma Interest Group, September 12, 2012, Boston, MA.
224. Hassan R, Ho M. Mesothelin targeted cancer immunotherapy. *Eur J Cancer* 2008;44:46-53.
225. Ho M, Hassan R, Zhang J, et al. Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients. *Clin Cancer Res* 2005;11:3814-3820.
226. Uehara N, Matsuoka Y, Tsubura A. Mesothelin promotes anchorage-independent growth and prevents anoikis via extracellular signal-regulated kinase signaling pathway in human breast cancer cells. *Mol Cancer Res* 2008;6:186-193.
227. Kaneko O, Gong L, Zhang J, et al. A binding domain on mesothelin for CA125/MUC16. *J Biol Chem* 2009;284:3739-3749.
228. Tang Z, Qian M, Ho M. The role of mesothelin in tumor progression and targeted therapy. *Anticancer Agents Med Chem* 2013;13:276-280.
229. Hassan R, Bullock S, Premkumar A, et al. Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. *Clin Cancer Res* 2007;13:5144-5149.

230. Palumbo C, Bei R, Procopio A, et al. Molecular targets and targeted therapies for malignant mesothelioma. *Curr Med Chem* 2008;15:855–867.
231. Roe OD, Creaney J, Lundgren S, et al. Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study. *Lung Cancer* 2008;61:235–243.
232. Rodriguez Portal JA, Rodriguez BE, Rodriguez RD, et al. Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure. *Cancer Epidemiol Biomarkers Prev* 2009;18:646–650.
233. Kreitman RJ, Hassan R, FitzGerald DJ, et al. Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P. *Clin Cancer Res* 2009;15:5274–5279.
234. Hassan R, Miller AC, Sharon E, et al. Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression. *Sci Transl Med* 2013;5:208ra147.
235. Law MR, Gregor A, Hodson ME, et al. Malignant mesothelioma of the pleura: a study of 52 treated and 64 untreated patients. *Thorax* 1984;39:255–259.
236. Ruffie P, Feld R, Minkin S, et al. Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients. *J Clin Oncol* 1989;7:1157–1168.
237. Ball DL, Cruickshank DG. The treatment of malignant mesothelioma of the pleura: review of a 5-year experience, with special reference to radiotherapy. *Am J Clin Oncol* 1990;13:4–9.
238. Holsti LR, Pyrhonen S, Kajanti M, et al. Altered fractionation of hemithorax irradiation for pleural mesothelioma and failure patterns after treatment. *Acta Oncol* 1997;36:397–405.
239. Alberts AS, Falkson G, Goedhals L, et al. Malignant pleural mesothelioma: a disease unaffected by current therapeutic maneuvers. *J Clin Oncol* 1988;6:527–535.
240. Linden CJ, Mercke C, Albrechtsson U, et al. Effect of hemithorax irradiation alone or combined with doxorubicin and cyclophosphamide in 47 pleural mesotheliomas: a nonrandomized phase II study. *Eur Respir J* 1996;9:2565–2572.
241. Herscher LL, Hahn SM, Kroog G, et al. Phase I study of paclitaxel as a radiation sensitizer in the treatment of mesothelioma and non-small-cell lung cancer. *J Clin Oncol* 1998;16:635–641.
242. Chen Y, Pandya K, Keng PP, et al. Schedule-dependent pulsed paclitaxel radiosensitization for thoracic malignancy. *Am J Clin Oncol* 2001;24:432–437.
243. Rusch VW, Rosenzweig K, Venkatraman E, et al. A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. *J Thorac Cardiovasc Surg* 2001;122:788–795.
244. Krayenbuehl J, Oertel S, Davis JB, et al. Combined photon and electron three-dimensional conformal versus intensity-modulated radiotherapy with integrated boost for adjuvant treatment of malignant pleural mesothelioma after pleuropneumectomy. *Int J Radiat Oncol Biol Phys* 2007;69:1593–1599.
245. Rice DC, Smythe WR, Liao Z, et al. Dose-dependent pulmonary toxicity after postoperative intensity-modulated radiotherapy for malignant pleural mesothelioma. *Int J Radiat Oncol Biol Phys* 2007;69:350–357.
246. Forster KM, Smythe WR, Starkschall G, et al. Intensity-modulated radiotherapy following extrapleural pneumonectomy for the treatment of malignant mesothelioma: clinical implementation. *Int J Radiat Oncol Biol Phys* 2003;55:606–616.
247. Munden RF, Erasmus JJ, Smythe WR, et al. Radiation injury to the liver after intensity-modulated radiation therapy in patients with mesothelioma: an unusual CT appearance. *AJR Am J Roentgenol* 2005;184:1091–1095.
248. Allen AM, Czerninska M, Janne PA, et al. Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma. *Int J Radiat Oncol Biol Phys* 2006;65:640–645.
249. Miles EF, Larrier NA, Kelsey CR, et al. Intensity-modulated radiotherapy for resected mesothelioma: the Duke experience. *Int J Radiat Oncol Biol Phys* 2008;71:1143–1150.
250. Kristensen CA, Notttrup TJ, Berthelsen AK, et al. Pulmonary toxicity following IMRT after extrapleural pneumonectomy for malignant pleural mesothelioma. *Radiother Oncol* 2009;92:96–99.
251. Baldini EH. Radiation therapy options for malignant pleural mesothelioma. *Semin Thorac Cardiovasc Surg* 2009;21:159–163.
252. Gupta V, Krug LM, Laser B, et al. Patterns of local and nodal failure in malignant pleural mesothelioma after extrapleural pneumonectomy and photon-electron radiotherapy. *J Thorac Oncol* 2009;4:746–750.
253. Gomez DR, Hong DS, Allen PK, et al. Patterns of failure, toxicity, and survival after extrapleural pneumonectomy and hemithoracic intensity-modulated radiation therapy for malignant pleural mesothelioma. *J Thorac Oncol* 2013;8:238–245.
254. Patel PR, Yoo S, Broadwater G, et al. Effect of increasing experience on dosimetric and clinical outcomes in the management of malignant pleural mesothelioma with intensity-modulated radiation therapy. *Int J Radiat Oncol Biol Phys* 2012;83:362–368.
255. Gupta V, Mychalczak B, Krug L, et al. Hemithoracic radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma. *Int J Radiat Oncol Biol Phys* 2005;63:1045–1052.
256. Rosenzweig KE, Fox JL, Zelefsky MJ, et al. A pilot trial of high-dose-rate intraoperative radiation therapy for malignant pleural mesothelioma. *Brachytherapy* 2005;4:30–33.
257. Rosenzweig KE, Zauderer MG, Laser B, et al. Pleural intensity-modulated radiotherapy for malignant pleural mesothelioma. *Int J Radiat Oncol Biol Phys* 2012;83:1278–1283.
258. Trovo M, Minatel E. Tomotherapy after pleurectomy or decortication or biopsy for malignant pleural mesothelioma. *J Thorac Oncol* 2013;8:e50–e51.
259. Agarwal PP, Seely JM, Matzinger FR, et al. Pleural mesothelioma: sensitivity and incidence of needle track seeding after image-guided biopsy versus surgical biopsy. *Radiology* 2006;241:589–594.
260. Bydder S, Phillips M, Joseph DJ, et al. A randomised trial of single-dose radiotherapy to prevent procedure tract metastasis by malignant mesothelioma. *Br J Cancer* 2004;91:9–10.
261. De Ruyscher D, Slotman B. Treatment of intervention sites of malignant pleural mesothelioma with radiotherapy: a Dutch-Belgian survey. *Radiother Oncol* 2003;68:299–302.
262. Lee C, Bayman N, Swindell R, et al. Prophylactic radiotherapy to intervention sites in mesothelioma: a systematic review and survey of UK practice. *Lung Cancer* 2009;66:150–156.
263. Ruffie P, Lehmann M, Galateau-Salle F, et al. Malignant mesothelioma. *Br J Cancer* 2001;84:49–50.
264. Davis SR, Tan L, Ball DL. Radiotherapy in the treatment of malignant mesothelioma of the pleura, with special reference to its use in palliation. *Australas Radiol* 1994;38:212–214.
265. Krayenbuehl J, Hartmann M, Lomax AJ, et al. Proton therapy for malignant pleural mesothelioma after extrapleural pneumonectomy. *Int J Radiat Oncol Biol Phys* 2010;78:628–634.
266. Lorentini S, Amichetti M, Spiazzi L, et al. Adjuvant intensity-modulated proton therapy in malignant pleural mesothelioma. A comparison with intensity-modulated radiotherapy and a spot size variation assessment. *Strahlenther Onkol* 2012;188:216–225.
267. Baud M, Strano S, Dechertres A, et al. Outcome and prognostic factors of pleural mesothelioma after surgical diagnosis and/or pleurodesis. *J Thorac Cardiovasc Surg* 2013;145:1305–1311.
268. Nojiri S, Gemba K, Aoe K, et al. Survival and prognostic factors in malignant pleural mesothelioma: a retrospective study of 314 patients in the west part of Japan. *Jpn J Clin Oncol* 2011;41:32–39.
269. Tanrikulu AC, Abakay A, Kaplan MA, et al. A clinical, radiographic and laboratory evaluation of prognostic factors in 363 patients with malignant pleural mesothelioma. *Respiration* 2010;80:480–487.
270. Francart J, Vaes E, Henrard S, et al. A prognostic index for progression-free survival in malignant mesothelioma with application to the design of phase II trials: a combined analysis of 10 EORTC trials. *Eur J Cancer* 2009;45:2304–2311.
271. Yan TD, Boyer M, Tin MM, et al. Extrapleural pneumonectomy for malignant pleural mesothelioma: outcomes of treatment and prognostic factors. *J Thorac Cardiovasc Surg* 2009;138:619–624.
272. Flores RM, Zakowski M, Venkatraman E, et al. Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center. *J Thorac Cardiovasc Surg* 2007;2:957–965.
273. Steele JP, Klabatsa A, Fennell DA, et al. Prognostic factors in mesothelioma. *Lung Cancer* 2005;49:S49–S52.
274. Neumann V, Rutten A, Scharmach M, et al. Factors influencing long-term survival in mesothelioma patients—results of the German mesothelioma register. *Int Arch Occup Environ Health* 2004;77:191–199.
275. Pass HI. Biomarkers and prognostic factors for mesothelioma. *Ann Cardiothorac Surg* 2012;1:449–456.
276. Abakay A, Komek H, Abakay O, et al. Relationship between 18 FDC PET-CT findings and the survival of 177 patients with malignant pleural mesothelioma. *Eur Rev Med Pharmacol Sci* 2013;17:1233–1241.
277. Weder W, Kestenholz P, Taverna C, et al. Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. *J Clin Oncol* 2004;22:3451–3457.
278. Weder W, Stahel RA, Bernhard J, et al. Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. *Ann Oncol* 2007;18:1196–1202.
279. Rea F, Marulli G, Bortolotti L, et al. Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM): Feasibility and results. *Lung Cancer* 2007;57:89–95.
280. Flores RM, Krug LM, Rosenzweig KE, et al. Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a phase II trial. *J Thorac Oncol* 2006;1:289–295.
281. Opitz I, Kestenholz P, Lardinio D, et al. Incidence and management of complications after neoadjuvant chemotherapy followed by extrapleural pneumonectomy for malignant pleural mesothelioma. *Eur J Cardiothorac Surg* 2006;29:579–584.
282. Buduhan G, Menon S, Aye R, et al. Trimodality therapy for malignant pleural mesothelioma. *Ann Thorac Surg* 2009;88:870–875.
283. de Perrot M, Feld R, Cho BC, et al. Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. *J Clin Oncol* 2009;27:1413–1418.
284. Krug LM, Pass HI, Rusch VW, et al. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. *J Clin Oncol* 2009;27:3007–3013.
285. Van Schil PE, Baas P, Gaafar R, et al. Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial. *Eur Respir J* 2010;36:1362–1369.

286. Pasello G, Marulli G, Polo V, et al. Pemetrexed plus carboplatin or cisplatin as neoadjuvant treatment of operable malignant pleural mesothelioma (MPM). *Anticancer Res* 2012;32:5393–5399.
287. Bille A, Belcher E, Raubenheimer H, et al. Induction chemotherapy, extrapleural pneumonectomy, and adjuvant radiotherapy for malignant pleural mesothelioma: experience of Guy's and St Thomas' hospitals. *Gen Thorac Cardiovasc Surg* 2012;60:289–296.
288. Okada K. Personal communication. Trimodality therapy with extrapleural pneumonectomy, radiation therapy, and chemotherapy for malignant pleural mesothelioma. *11th International Conference of the International Mesothelioma Interest Group*. 2012.
289. Neragi-Miandoab S, Richards WC, Sugarbaker DJ. Morbidity, mortality, mean survival, and the impact of histology on survival after pleurectomy in 64 patients with malignant pleural mesothelioma. *Int J Surg* 2008;6:293–297.
290. Luckraz H, Rahman M, Patel N, et al. Three decades of experience in the surgical multi-modality management of pleural mesothelioma. *Eur J Cardiothorac Surg* 2010;37:552–556.
291. Bolukbas S. Long-term outcome after radical pleurectomy followed by chemoradiation for malignant pleural mesothelioma: a 10-year single center experience. *11th International Conference of the International Mesothelioma Interest Group*. September 12, 2012, Boston, MA.
292. Cameron RB, Olevsky O, Selch M. The timing of chemotherapy in the multimodality therapy of pleural mesothelioma. *11th International Conference of the International Mesothelioma Interest Group*, September 12, 2012, Boston, MA.
293. Friedberg J, Culligan MJ, Mick R. Radical pleurectomy and intraoperative porfimer sodium photodynamic therapy for malignant. *11th International Conference of the International Mesothelioma Interest Group*. September 12, 2012, Abstract.
294. Bille A, Okiror L, Lang-Lazdunski L. Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine followed by adjuvant chemotherapy: survival analysis in 65 consecutive patients. *11th International Conference of the International Mesothelioma Interest Group*. September 12, 2012, Boston, MA.
295. Lang-Lazdunski L, Bille A, Lal R, et al. Pleurectomy/decortication is superior to extrapleural pneumonectomy in the multimodality management of patients with malignant pleural mesothelioma. *J Thorac Oncol* 2012;7:737–743.
296. Rena O, Casadio C. Extrapleural pneumonectomy for early stage malignant pleural mesothelioma: a harmful procedure. *Lung Cancer* 2012;77:151–155.
297. Sorensen JB, Ravn J, Krisetensen C. Two simultaneous consecutive non-randomized cohorts of operable patients with MPM receiving induction therapy followed either by EPP and postoperative radiotherapy or pleurectomy decortication alone. Presented at International Mesothelioma Interest Group Meeting, October 2012, Boston, MA.
298. Pass H. Mesothelioma revisited: a multidisciplinary approach. Presented at International Mesothelioma Interest Group Meeting, October 2012, Boston, MA.
299. Campbell NP, Kunnavakkam R, Leigh N, et al. Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium. *Lung Cancer* 2012;78:76–80.
300. Garland LL, Chansky K, Wozniak AJ, et al. Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509. *J Thorac Oncol* 2011;6:1938–1945.
301. Molina JR, Mandrekar S, Ziegler K. A phase II study of the VEGFR inhibitor pazopanib (P) in patients with newly diagnosed or relapsed malignant pleural mesothelioma (MPM): an NCCTG study. *J Thorac Oncol* 2009;4:S456.
302. Nowak AK, Millward MJ, Creaney J, et al. A phase II study of intermittent sunitinib malate as second-line therapy in progressive malignant pleural mesothelioma. *J Thorac Oncol* 2012;7:1449–1456.
303. Laurie SA, Gupta A, Chu Q, et al. Brief report: a phase II study of sunitinib in malignant pleural mesothelioma. The NCIC Clinical Trials Group. *J Thorac Oncol* 2011;6:1950–1954.